Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
Astrazeneca Pharma and Sun Pharma form second brand partnership     Back
(17 Nov 2025)
Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market & distribute SZC in India under different brand names; AstraZeneca will market SZC as Lokelma® whereas Sun Pharma will promote and distribute the therapy as Gimliand®. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule.
Top